Or Google, "Local company builds device to detect explosives." For anyone who hasn't seen this video already, pause it at 1:32 and check out the passenger checkpoint walk-thru system on the left and the conveyorized package screening device on the right. I wish they would discuss these and everything else in the development pipeline in more detail on their conference calls.
8-K out today, they received the cash and issued the 37.5 million shares. Looking at the selling today I have to think there were some people new to DLYT who didn't know this was coming. I held on to 10,000 of my .037 shares but won't be adding any. I'll let the $370 ride.
Cramer didn't tweet this. Someone under the handle @BullsBearsWin did. It's an account with ZERO followers. Stay classy, princess.
LS sales of $10-12 million in 2014 will be amazing considering that, "Revenues from sales of Lymphoseek for the fourth quarter of 2013 were $343,000." Meaning Q4 sales of LS were $686,000. Those 2014 numbers are pretty lofty guidance, now they have to produce.
University of Phoenix PhD? Why post something so stupid? Come on.
Darryl Jones' Education
University of Alabama in Huntsville
Ph.D., Optical Science and Engineering
1992 – 1999
1982 – 1984
DMRJ is a parasite and they control this company. Anyone thinking otherwise has their head in the sand. The number of outstanding shares increased from 59.3 million to 61.86 million recently (more DMRJ conversion), that explains the endless supply of shares available at .80 these days.
I mentioned two overhangs, I could have mentioned more. You make a carnival barker statement, "last chance to buy below $2.00," and you say I have motives. That's funny. Have a nice day.
Are you saying the anticipated weak last quarter sales of LS is already priced in? And the almost guaranteed further dilution in 2014 is as well? I'm willing to wait until after they report to decide whether or not to get back into this. If I'm wrong...meh.
New Clinical Study Results of Guided Therapeutics' LuViva Advanced Cervical Scan to be Presented at Top International Medical Conference
LONDON--(BUSINESS WIRE)-- The Secretary General of the International Federation for Cervical Pathology and Colposcopy (IFCPC), Dr. James Bentley, will present results of a new clinical study of the LuViva(R) Advanced Cervical Scan at the 15th World Congress for Cervical Pathology and Colposcopy, being held May 26 - 30 in London. The LuViva, a non-invasive device used to detect cervical disease instantly at the point of care, is a product of Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP).
The title of the abstract is "LuViva Cervical Scan as a Triage Test to Reduce Unnecessary Colposcopy and Biopsy." The study was conducted by Dr. James Bentley, who is also Professor and Division Head of Gynecology Oncology at Dalhousie University School of Medicine in Halifax, Nova Scotia and Dr. Richard Zane at the Atlanta Women's Research Institute in Atlanta, Georgia.
"We believe that the results of this new clinical study, to be presented to the leading cervical cancer experts from around the world, will further validate LuViva's future role in improving the diagnosis of cervical cancer in women across the globe," said Gene Cartwright, Chief Executive Officer of Guided Therapeutics. "There is a critical unmet need in gynecology for a product like LuViva that provides immediate results at the point of care, eliminates unnecessary procedures and finds disease that can be missed by the standard of care. We believe that the opportunity for LuViva, particularly in international markets, is tremendous and we plan on capturing that opportunity."
"We also want to thank Dr. Bentley and Dr. Zane for their hard work and for recognizing the potential of LuViva at an early stage," said Mr. Cartwright. "Once published, the study will be used in our approved international markets to support our distributors and LuViva's expanding product launch."
Looks like identical language from previous 10-Q. As (s)(c)(u)(m)my as DMRJ is, I don't think they decline to extend the deadline. Unless of course, IMSC fails to get checkpoint approval. Then, well, they're not in a happy place.
Lol right now. Who was the "weak" one that just dumped 100,000 shares at .75? I think we know. This is a trading stock. You can't view any company that has an oppressive financing deal with Platinum as anything else than that.
This had all the elements of a Platinum pump and dump, the only thing missing was that idiot carnival barker Uri Landesman. I guess CNBC no longer allows him air time to execute these things the way he did a few years ago so now they get the beholden management to stockpile a few sales PRs the week before a disappointing earnings call. Good job, DMRJ!
Very short notice for an earnings call. I suspect this is to get the bad news out (last quarter sales) while good news (recent sales) is still fresh in the minds of shareholders. Again today, an endless supply of .80 shares available.
Less than 30 minutes to go and IMSC is red. Not all that surprising as DMRJ continues to dump a seemingly endless supply of shares into any good news.
Nice sale, let's see if they can keep any kind of momentum going now. It would be nice to see one of these every week.